8-K: TG Therapeutics Reports Strong 2025 Revenue, Raises 2026 Outlook

TG Therapeutics announced preliminary strong 2025 revenue for BRIUMVI and provided optimistic 2026 financial guidance and key development milestones.

Summary

• Preliminary total global full year 2025 revenue is approximately $616 million.
• Preliminary U.S. BRIUMVI net product revenue for the fourth quarter and full year 2025 is approximately $182 million and $594 million, respectively.
• Full Year 2026 target total global revenue is approximately $875-900 million.
• Full Year 2026 target U.S. BRIUMVI net product revenue is approximately $825-850 million.
• Full year 2026 target operating expense (R&D and SG&A, excluding non-cash compensation) is approximately $350 million.
• An additional $100 million in 2026 expenses is allocated for subcutaneous BRIUMVI inventory build and secondary manufacturer start-up costs.
• Key development milestones are anticipated for 2026 and early 2027, including pivotal data for consolidated IV and subcutaneous BRIUMVI, and preliminary data for azer-cel in Progressive MS.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results for 2025, provides significantly increased revenue guidance for 2026, and outlines multiple promising development milestones for its key product BRIUMVI and pipeline asset azer-cel, indicating robust growth and strategic expansion.

Positives

• BRIUMVI delivered strong commercial performance in 2025, reinforcing confidence in its multi-billion dollar market opportunity.
• The company has achieved significant market share capture since launch, positioning it for long-term revenue growth and cash flow.
• Development programs for consolidated IV BRIUMVI dosing and a self-administered subcutaneous form are expected to drive revenue acceleration if approved.
• Plans to initiate multiple exploratory studies could expand BRIUMVI beyond Multiple Sclerosis (MS), providing an additional growth lever.
• Excitement remains for azer-cel, an allogeneic CAR-T therapy, in autoimmune indications, starting with progressive forms of MS.
• The company provided significantly increased revenue guidance for the full year 2026, projecting total global revenue of $875-900 million.

Risks

• Preliminary financial results for 2025 are unaudited, subject to final closing procedures and adjustment, and may prove materially inaccurate.
• Trends in prescriptions for BRIUMVI may not be maintained, or prescriptions may not be filled.
• Failure to obtain and maintain adequate payor coverage for BRIUMVI.
• Healthcare professional interest in BRIUMVI may not be sustained, impacting sales momentum.
• BRIUMVI revenue targets for 2026 may not be achieved.
• Failure to obtain and maintain requisite regulatory approvals, including satisfying post-approval requirements, could impact product availability and labeling.
• Variations from projections about BRIUMVI's potential market may occur due to factors like regulatory-imposed labeling modifications or safety signals.
• The company's ability to meet post-approval compliance obligations (product quality, distribution, pharmacovigilance, sales, and marketing) is crucial.
• Reliance on third parties for manufacturing, distribution, supply, and other support functions for clinical and commercial products, including BRIUMVI, poses risks.
• Individual or aggregate patient clinical experience in the post-marketing setting may differ from that demonstrated in controlled clinical trials.
• The company may not achieve its 2026 development pipeline anticipated milestones or goals within the projected timeframe or at all.
• The subcutaneous Phase 3 program for ublituximab may not be successful, approved by the FDA, or achieve commercial acceptance.
• The ENHANCE Phase 3 trial may not be successful, approved by the FDA, or achieve commercial acceptance.
• The company may not proceed with the development of BRIUMVI in Myasthenia Gravis (MG) and azer-cel following preliminary studies.
• Uncertainties are inherent in research and development activities.
• Regulatory developments, legislative actions, executive orders, tariffs, and policy changes in the U.S. and other jurisdictions could impact operations.
• General political, economic, and business conditions may affect financial performance.

Future Outlook

The company projects strong growth for 2026, targeting total global revenue of $875-900 million, primarily driven by U.S. BRIUMVI sales of $825-850 million. They anticipate revenue acceleration from new BRIUMVI formulations (consolidated IV and subcutaneous) and plan to expand BRIUMVI into new indications beyond MS, as well as advance their azer-cel program for autoimmune diseases. Several key clinical data readouts are expected in 2026 and early 2027.

Management Comments

• "BRIUMVI continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for BRIUMVI."
• "With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow."
• "Our development programs for consolidated IV BRIUMVI dosing and self-administered subcutaneous form of BRIUMVI are expected to drive revenue acceleration over the short and mid-term if approved."
• "We plan to initiate multiple exploratory studies that could expand BRIUMVI beyond MS, providing an additional lever for growth and underscoring its potential as a pipeline-in-a-product."
• "We also remain excited about the potential of azer-cel, our allogeneic CAR-T in autoimmune indications, starting with progressive forms of MS."
• "Taken together, we believe we are executing a strategy designed to deliver sustained growth and long-term value for patients and shareholders."

Industry Context

BRIUMVI targets CD20-expressing B-cells, a well-established therapeutic approach for autoimmune disorders like Relapsing Multiple Sclerosis (RMS). The company's focus on glycoengineered antibodies for efficient B-cell depletion at low doses positions it within the competitive MS treatment landscape. The strategic expansion into consolidated IV and subcutaneous forms, alongside exploratory studies beyond MS, indicates a proactive approach to broaden market reach and enhance competitive advantage against other MS therapies.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue performance, increased guidance, and promising pipeline developments, potentially leading to increased share value.
• Patients: Potential for improved treatment options with new BRIUMVI formulations (consolidated IV, subcutaneous) and expansion into new indications, as well as the development of azer-cel for autoimmune diseases.
• Employees: Continued growth and expansion could lead to job stability and potential opportunities.
• Healthcare Professionals: New data and formulations for BRIUMVI could offer more flexible and effective treatment options for RMS patients.

Next Steps

• Complete financial closing procedures and adjustments for the preliminary 2025 financial results.
• Announce pivotal topline data for the ENHANCE trial (consolidated IV BRIUMVI dosing) mid-year 2026.
• Present preliminary Phase 1 azer-cel data in Progressive MS in the second half of 2026.
• Announce pivotal topline data for subcutaneous BRIUMVI (ublituximab) year-end 2026/1Q 2027.
• Commence a registration-directed trial for BRIUMVI in an indication outside of MS.
• Commence additional exploratory studies for BRIUMVI and azer-cel in autoimmune disease (outside MS).

Key Dates

Recommendation

The company has demonstrated robust commercial execution with BRIUMVI, exceeding expectations in 2025 and providing significantly higher revenue guidance for 2026. The strategic pipeline advancements, including new BRIUMVI formulations and expansion into new indications, coupled with the promising azer-cel program, suggest sustained long-term growth potential. Despite inherent risks in biopharmaceutical development, the current trajectory and management's confidence in a multi-billion dollar opportunity for BRIUMVI make it an attractive investment.

Keywords

TG Therapeutics, TGTX, BRIUMVI, ublituximab, multiple sclerosis, MS, relapsing multiple sclerosis, RMS, autoimmune disease, azer-cel, CAR-T, biopharmaceutical, revenue guidance, financial results, clinical trials, FDA